Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome

被引:95
作者
Macut, D. [1 ]
Tziomalos, K. [2 ]
Bozic-Antic, I. [1 ]
Bjekic-Macut, J. [3 ]
Katsikis, I. [4 ]
Papadakis, E. [4 ]
Andric, Z. [3 ]
Panidis, D. [4 ]
机构
[1] Univ Belgrade, Fac Med, Clin Endocrinol Diabet & Dis Metab, Karnegijeva 4, Belgrade 11000, Serbia
[2] Aristotle Univ Thessaloniki, AHEPA Hosp, Sch Med, Propedeut Dept Internal Med 1, Thessaloniki 54636, Greece
[3] Univ Belgrade, Fac Med, CHC Bezanijska Kosa, Karnegijeva 4, Belgrade 11080, Serbia
[4] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Obstet & Gynecol 2, Div Endocrinol & Human Reprod,Med Sch, Thessaloniki 54642, Greece
关键词
non-alcoholic fatty liver disease; insulin resistance; lipid acumulation product; polycystic ovary syndrome; metabolic syndrome; HORMONE-BINDING GLOBULIN; HEPATIC STEATOSIS; ALANINE AMINOTRANSFERASE; CARDIOVASCULAR RISK; METABOLIC SYNDROME; OBESE WOMEN; DIAGNOSIS; INDEX; METFORMIN; BIOPSY;
D O I
10.1093/humrep/dew076
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
What are the most relevant factors associated with non-alcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS)? Insulin resistance (IR) and lipid accumulation product (LAP) are independently associated with NAFLD in PCOS. Obesity and IR are frequently present in both women with PCOS and subjects having NAFLD. The coexistence of PCOS and NAFLD might synergistically increase the risk for both type 2 diabetes (T2DM) and cardiovascular disease (CVD). LAP, calculated from waist circumference (WC) and triglycerides (TGs) concentrations [(WC-58) x TGs], has been shown to represent an integrated marker of cardiometabolic risk in women with PCOS. This cross-sectional study included 600 Caucasian women diagnosed with PCOS by the Rotterdam criteria between May 2008 and May 2013. The study was done at the university hospitals in Belgrade, Serbia and Thessaloniki, Greece. All subjects underwent anthropometric measurements and analyses of fasting blood glucose, insulin, lipids, total testosterone and SHBG, as well as liver tests (transaminases, gamma-glutamyltransaminase, total bilirubin and alkaline phosphatase). Calculations for a NAFLD liver fat score (NAFLD-LFS) (with, accordingly, determination of metabolic syndrome and testing for T2DM) as well as homeostasis model assessment of IR (HOMA-IR), LAP as a marker of visceral adiposity, and free androgen index (FAI) were performed. We evaluated the prevance of NAFLD and analyzed associations of the above variables with NAFLD. NAFLD was more prevalent in patients with PCOS than in controls (50.6 versus 34.0%, respectively). Women with PCOS had higher readings for WC, LAP, insulin and HOMA-IR, total cholesterol and TGs than controls (P < 0.001). In PCOS women, the NAFLD-LFS significantly (P < 0.001) correlated with WC, BMI, glucose, HOMA-IR, TGs, LAP and FAI. In multivariate logistic regression, HOMA-IR and LAP were independently associated with NAFLD (P a parts per thousand currency sign 0.001). A possible weakness of the study may be the absence of structural confirmation of liver status. Hovewer, liver biopsy is invasive, difficult to perform in large populations and carries some risk of complications while magnetic resonance spectroscopy does not provide any information regarding the presence of fibrosis and is not routinely available. Another possible limitation could be the measurement of total testosterone by radioimmunoassay, which can be inaccurate when determining low levels of testosterone. Finally, fewer controls than subjects in the study group could have affected the significance of the results. There is a debate on the most accurate clinical method for diagnosing liver disease as an early predictor of T2DM and CVD in general population and in PCOS women. There current study provided data on this issue from a cohort of Caucasian women with PCOS. The study was supported by a research grant by the Serbian Ministry of Science and Education (grant nos 41009 and 175032). All authors have no competing interests.
引用
收藏
页码:1347 / 1353
页数:7
相关论文
共 49 条
[1]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]   The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population [J].
Bedogni, Giorgio ;
Bellentani, Stefano ;
Miglioli, Lucia ;
Masutti, Flora ;
Passalacqua, Marilena ;
Castiglione, Anna ;
Tiribelli, Claudio .
BMC GASTROENTEROLOGY, 2006, 6 (1)
[3]   A simple index of lipid overaccumulation is a good marker of liver steatosis [J].
Bedogni, Giorgio ;
Kahn, Henry S. ;
Bellentani, Stefano ;
Tiribelli, Claudio .
BMC GASTROENTEROLOGY, 2010, 10
[4]  
Bjekic-Macut J, 2015, HORM-INT J ENDOCRINO, DOI [10.14310/horm.12002.11592, DOI 10.14310/HORM.12002.11592]
[5]   Risk of T2DM and impaired fasting glucose among PCOS subjects: Results of an 8-year follow-up [J].
Boureaux M.Y. ;
Talbott E.O. ;
Kip K.E. ;
Brooks M.M. ;
Witchel S.F. .
Current Diabetes Reports, 2006, 6 (1) :77-83
[6]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[7]   Practices of liver biopsy in France: Results of a prospective nationwide survey [J].
Cadranel, JF ;
Rufat, P ;
Degos, F .
HEPATOLOGY, 2000, 32 (03) :477-481
[8]   The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Diehl, Anna Mae ;
Brunt, Elizabeth M. ;
Cusi, Kenneth ;
Charlton, Michael ;
Sanyal, Arun J. .
HEPATOLOGY, 2012, 55 (06) :2005-2023
[9]   Metformin and its clinical use: new insights for an old drug in clinical practice [J].
Cicero, Arrigo F. G. ;
Tartagni, Elisa ;
Ertek, Sibel .
ARCHIVES OF MEDICAL SCIENCE, 2012, 8 (05) :907-917
[10]   Omega-3 Fatty Acid Supplementation Decreases Liver Fat Content in Polycystic Ovary Syndrome: A Randomized Controlled Trial Employing Proton Magnetic Resonance Spectroscopy [J].
Cussons, Andrea J. ;
Watts, Gerald F. ;
Mori, Trevor A. ;
Stuckey, Bronwyn G. A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (10) :3842-3848